Share FDA D.I.S.C.O. Burst Edition: FDA approval of Fyarro (sirolimus protein-bound particles for injectable suspension (albumin-bound)) for locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor
FDA D.I.S.C.O. Burst Edition: FDA approval of Fyarro (sirolimus protein-bound particles for injectable suspension (albumin-bound)) for locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor
Listen to a soundcast of the November 22, 2021, FDA approval of Fyarro (sirolimus protein-bound particles for injectable suspension (albumin-bound) for locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor.
...more
View all episodesBy U.S. Food and Drug Administration, Center for Drug Evaluation and Research
4.4
1414 ratings
FDA D.I.S.C.O. Burst Edition: FDA approval of Fyarro (sirolimus protein-bound particles for injectable suspension (albumin-bound)) for locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor
Listen to a soundcast of the November 22, 2021, FDA approval of Fyarro (sirolimus protein-bound particles for injectable suspension (albumin-bound) for locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor.